

# Kevin A Hay

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6892311/publications.pdf>

Version: 2024-02-01

34  
papers

4,353  
citations

430874

18  
h-index

434195

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

5695  
citing authors

#	ARTICLE	IF	CITATIONS
1	Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. <i>Blood Reviews</i> , 2021, 45, 100707.	5.7	137
2	Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T). <i>Cmaj</i> , 2021, 193, E1300-E1302.	2.0	2
3	Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2021, 10, 35.	5.3	11
4	Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study. <i>British Journal of Haematology</i> , 2020, 191, e14-e19.	2.5	1
5	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. <i>Blood</i> , 2020, 135, 1650-1660.	1.4	222
6	Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas. <i>Acta Oncologica</i> , 2020, 59, 766-774.	1.8	9
7	A Rapid and Sensitive Nucleic Acid Amplification Technique for Mycoplasma Screening of Cell Therapy Products. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 393-399.	4.1	16
8	Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor cell cytokine release syndrome. <i>British Journal of Haematology</i> , 2020, 190, e150-e154.	2.5	32
9	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. <i>Blood</i> , 2019, 134, 636-640.	1.4	127
10	Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S9-S10.	2.0	7
11	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. <i>Blood</i> , 2019, 133, 1652-1663.	1.4	277
12	Multivariate Analyses Indicate That the Cytokine Response to Lymphodepletion May be Better Associated Than Lymphodepletion Intensity with the Efficacy of CD19 CAR-T Cell Immunotherapy for Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S179-S180.	2.0	1
13	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. <i>Blood</i> , 2019, 133, 1876-1887.	1.4	230
14	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. <i>Blood Advances</i> , 2019, 3, 3062-3069.	5.2	74
15	Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. <i>Blood Advances</i> , 2019, 3, 3590-3601.	5.2	52
16	CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era. <i>Immunotherapy</i> , 2018, 10, 251-254.	2.0	5
17	Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. <i>Blood</i> , 2018, 131, 121-130.	1.4	374
18	Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR) T cell therapy. <i>British Journal of Haematology</i> , 2018, 183, 364-374.	2.5	131

#	ARTICLE	IF	CITATIONS
19	Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL. <i>Blood</i> , 2018, 132, 299-299.	1.4	43
20	Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 1415-1415.	1.4	6
21	Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 1681-1681.	1.4	1
22	Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 1680-1680.	1.4	31
23	Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival. <i>Blood</i> , 2018, 132, 281-281.	1.4	0
24	Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies. <i>Drugs</i> , 2017, 77, 237-245.	10.9	112
25	Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. <i>Cancer Discovery</i> , 2017, 7, 1404-1419.	9.4	945
26	Infectious Complications of CD19-Targeted Chimeric Antigen Receptor-Modified T Cell Immunotherapy. <i>Open Forum Infectious Diseases</i> , 2017, 4, S698-S699.	0.9	1
27	Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. <i>Blood</i> , 2017, 130, 2295-2306.	1.4	774
28	Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. <i>Journal of Clinical Oncology</i> , 2017, 35, 3010-3020.	1.6	568
29	Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy. <i>Blood</i> , 2017, 130, 805-805.	1.4	0
30	Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 276-282.	1.3	14
31	Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose. <i>Blood</i> , 2016, 128, 1852-1852.	1.4	10
32	Effect of Place of Residence and Treatment on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma in British Columbia. <i>Oncologist</i> , 2014, 19, 283-290.	3.7	26
33	Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8552-8552.	1.6	0
34	Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. <i>MABs</i> , 2010, 2, 53-66.	5.2	114